AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (currently amended): A pharmaceutical composition comprising an epothilone together with a pharmaceutically acceptable carrier comprising 10 to 62.5 % v/v water, 12.5 to 65 % v/v ethanol, and 10 to 25 % v/v polyoxyethylene sorbitan monooleate, wherein the composition comprises at least one cyclodextrin, and wherein the epothilone is provided in a therapeutically acceptable concentration at a dosage level between about 1 mg/m² and about 200 mg/m² upon-administration to a patient.

2-3. (canceled)

- 4. (previously presented): The pharmaceutical composition of Claim 1, wherein the cyclodextrin is selected from the group consisting of β -cyclodextrin, hydroxypropyl- β -cyclodextrin, and sulfopropyl- β -cyclodextrin.
- 5. (original): The pharmaceutical composition of Claim 4, wherein the epothilone is selected from the group consisting of epothilone D, epothilone B, 9,10-dehydro-epothilone D, and 9,10-dehydro-epothilone B.
- 6. (original): The pharmaceutical composition of Claim 5, wherein the epothilone is epothilone D.
- 7. (original): The pharmaceutical composition of Claim 6, wherein the cyclodextrin is hydroxypropyl-β-cyclodextrin.

- 8. (original): The pharmaceutical composition of Claim 6, wherein the cyclodextrin is sulfopropyl-β-cyclodextrin.
- 9-14. (canceled)
- 15. (currently amended): A method of preparing a pharmaceutical composition, said method comprising the steps of obtaining a lyophilate comprising an epothilone and a cyclodextrin; and dissolving said lyophilate in a [[suitable]] reconstitution solvent comprising 10 to 62.5 % v/v water, 12.5 to 65 % v/v ethanol, and 10 to 25 % v/v polyoxyethylene sorbitan
- 16. (currently amended): The method of Claim 15, wherein the reconstitution solvent comprises one or more of an alcohol and a glycol between about 15 and about 20 % v/v polyoxyethylene sorbitan monooleate.
- 17-21. (canceled)

monooleate.

- 22. (original): A soft gel cap comprising a pharmaceutical composition of Claim 1.
- 23. (new): The pharmaceutical composition of Claim 1, wherein the epothilone is provided at a dosage level between about 10 mg/m² and about 150 mg/m².
- 24. (new): The pharmaceutical composition of Claim 1, wherein the epothilone is provided at a dosage level between about 15 mg/m² and about 50 mg/m².